vs
Global Medical REIT Inc.（GMRE）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
Global Medical REIT Inc.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.1倍（$38.4M vs $35.5M），Global Medical REIT Inc.净利率更高（-16.0% vs -304.2%，领先288.2%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 9.2%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 4.6%）
医疗地产信托公司（MPT）是总部位于美国阿拉巴马州伯明翰的国际房地产投资信托基金，主要在美国和欧洲投资收购医疗机构与营利性医疗控股公司。多数收购采用售后回租模式：原业主将物业出售给MPT后转为承租方，租户通常需要签订长期三净租约。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
GMRE vs RXRX — 直观对比
营收规模更大
GMRE
是对方的1.1倍
$35.5M
营收增速更快
RXRX
高出672.5%
9.2%
净利率更高
GMRE
高出288.2%
-304.2%
两年增速更快
RXRX
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $38.4M | $35.5M |
| 净利润 | $-6.1M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | -16.0% | -304.2% |
| 营收同比 | 9.2% | 681.7% |
| 净利润同比 | -309.2% | 39.6% |
| 每股收益（稀释后） | $-0.48 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMRERXRX
| Q4 25 | $38.4M | $35.5M | ||
| Q3 25 | $37.2M | $5.2M | ||
| Q2 25 | $38.0M | $19.2M | ||
| Q1 25 | $34.6M | $14.7M | ||
| Q4 24 | $35.2M | $4.5M | ||
| Q3 24 | $34.3M | $26.1M | ||
| Q2 24 | $34.2M | $14.4M | ||
| Q1 24 | $35.1M | $13.8M |
净利润GMRERXRX
| Q4 25 | $-6.1M | $-108.1M | ||
| Q3 25 | $-5.1M | $-162.3M | ||
| Q2 25 | $585.0K | $-171.9M | ||
| Q1 25 | $3.7M | $-202.5M | ||
| Q4 24 | $2.9M | $-178.9M | ||
| Q3 24 | $3.4M | $-95.8M | ||
| Q2 24 | $-2.0M | $-97.5M | ||
| Q1 24 | $2.3M | $-91.4M |
毛利率GMRERXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率GMRERXRX
| Q4 25 | — | -304.8% | ||
| Q3 25 | — | -3327.6% | ||
| Q2 25 | — | -916.8% | ||
| Q1 25 | — | -1297.9% | ||
| Q4 24 | — | -4042.4% | ||
| Q3 24 | — | -377.1% | ||
| Q2 24 | — | -697.4% | ||
| Q1 24 | — | -698.4% |
净利率GMRERXRX
| Q4 25 | -16.0% | -304.2% | ||
| Q3 25 | -13.6% | -3135.3% | ||
| Q2 25 | 1.5% | -894.2% | ||
| Q1 25 | 10.8% | -1373.3% | ||
| Q4 24 | 8.4% | -3935.5% | ||
| Q3 24 | 9.9% | -367.5% | ||
| Q2 24 | -5.7% | -676.6% | ||
| Q1 24 | 6.6% | -662.4% |
每股收益（稀释后）GMRERXRX
| Q4 25 | $-0.48 | $-0.17 | ||
| Q3 25 | $-0.45 | $-0.36 | ||
| Q2 25 | $-0.01 | $-0.41 | ||
| Q1 25 | $0.03 | $-0.50 | ||
| Q4 24 | $-0.04 | $-0.56 | ||
| Q3 24 | $0.14 | $-0.34 | ||
| Q2 24 | $-0.05 | $-0.40 | ||
| Q1 24 | $0.01 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1M | $743.3M |
| 总债务越低越好 | $1.2M | $9.6M |
| 股东权益账面价值 | $509.8M | $1.1B |
| 总资产 | $1.2B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.00× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资GMRERXRX
| Q4 25 | $9.1M | $743.3M | ||
| Q3 25 | $7.1M | $659.8M | ||
| Q2 25 | $6.6M | $525.1M | ||
| Q1 25 | $5.4M | $500.5M | ||
| Q4 24 | $6.8M | $594.4M | ||
| Q3 24 | $5.7M | $427.6M | ||
| Q2 24 | $5.0M | $474.3M | ||
| Q1 24 | $1.3M | $296.3M |
总债务GMRERXRX
| Q4 25 | $1.2M | $9.6M | ||
| Q3 25 | $1.2M | $11.9M | ||
| Q2 25 | $14.2M | $14.2M | ||
| Q1 25 | $14.3M | $16.4M | ||
| Q4 24 | $14.4M | $19.0M | ||
| Q3 24 | $14.5M | $20.5M | ||
| Q2 24 | $14.7M | $22.9M | ||
| Q1 24 | $25.7M | — |
股东权益GMRERXRX
| Q4 25 | $509.8M | $1.1B | ||
| Q3 25 | $485.3M | $1.0B | ||
| Q2 25 | $503.2M | $919.1M | ||
| Q1 25 | $517.4M | $933.9M | ||
| Q4 24 | $534.1M | $1.0B | ||
| Q3 24 | $542.6M | $524.6M | ||
| Q2 24 | $556.4M | $584.4M | ||
| Q1 24 | $575.0M | $401.2M |
总资产GMRERXRX
| Q4 25 | $1.2B | $1.5B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.3B | $1.4B | ||
| Q3 24 | $1.2B | $726.5M | ||
| Q2 24 | $1.2B | $775.9M | ||
| Q1 24 | $1.3B | $557.8M |
负债/权益比GMRERXRX
| Q4 25 | 0.00× | 0.01× | ||
| Q3 25 | 0.00× | 0.01× | ||
| Q2 25 | 0.03× | 0.02× | ||
| Q1 25 | 0.03× | 0.02× | ||
| Q4 24 | 0.03× | 0.02× | ||
| Q3 24 | 0.03× | 0.04× | ||
| Q2 24 | 0.03× | 0.04× | ||
| Q1 24 | 0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $73.6M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流GMRERXRX
| Q4 25 | $73.6M | $-46.1M | ||
| Q3 25 | $17.6M | $-117.4M | ||
| Q2 25 | $22.1M | $-76.4M | ||
| Q1 25 | $12.3M | $-132.0M | ||
| Q4 24 | $70.0M | $-115.4M | ||
| Q3 24 | $16.3M | $-59.2M | ||
| Q2 24 | $18.9M | $-82.2M | ||
| Q1 24 | $14.3M | $-102.3M |
自由现金流GMRERXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率GMRERXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度GMRERXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率GMRERXRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 37.84× | — | ||
| Q1 25 | 3.28× | — | ||
| Q4 24 | 23.83× | — | ||
| Q3 24 | 4.81× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 6.18× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
